JCR Pharmaceuticals says Japan health ministry grants orphan drug status to DMD drug givinostat

Bitget2026/09/28 16:55

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Japan’s health ministry granted orphan drug designation to givinostat for Duchenne muscular dystrophy, supporting JCR’s Japan development plan.
The drug also received Priority Examination status; JCR targets a Japan marketing application by end-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JCR Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609281255BIZWIRE_USPR_____20260928_BW668942) on September 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

JCR Pharmaceuticals says Japan health ministry grants orphan drug status to DMD drug givinostat

You may also like

Crypto prices